Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).
Craven House Capital plc
("Craven House" or the "Company")
Issue of Equity and Directors' Dealing
The Company announces that Balbir Bindra and Calum Morrison have each been issued 4,904 new ordinary shares ("New Ordinary Shares") as per the terms of their respective appointment letters.
As a result of this issue, Balbir Bindra will hold 14,440 Ordinary Shares, representing 0.5% per cent of the Company's issued share capital.
As a result of this issue, Calum Morrison will hold 7,356 Ordinary Shares, representing 0.2% per cent of the Company's issued share capital.
Admission of the New Ordinary Shares to trading on AIM and Total Voting Rights
Application will be made for admission of the 9,808 New Ordinary Shares to be issued on the AIM Market of the London Stock Exchange, which is expected to take place at 8.00 a.m. on or around 4 March 2020 ("Admission").
The New Ordinary Shares will, when issued, be credited as fully paid and will rank equally in all respects with the existing Ordinary Shares, including the right to receive any dividend or other distribution declared, made or paid after Admission.
For the purposes of the Financial Conduct Authority's Disclosure and Transparency Rules ("DTRs"), the issued ordinary share capital of the Company following Admission will consist of 3,063,589 Ordinary Shares of $1.00 with voting rights attached (one vote per Ordinary Share). There are no Ordinary Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, the Company under the DTRs.
~ Ends ~
For further information please contact:
| Craven House Capital Plc Mark Pajak
| Tel: 0203 286 8130
|
| SI Capital Broker Nick Emerson | Tel: 01483 413500 |
|
SPARK Advisory Partners Limited Nominated Adviser Matt Davis/Mark Brady
|
Tel: 0203 368 3550
|
About Craven House Capital:
The Company's Investing Policy is to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets globally in any geographic jurisdiction. The company will invest in both developed and developing markets providing long term patient capital and is often involved in special situations, restructuring, expansion and turn around investments in crisis and transitioning economies.
PDMR Notifications
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | 1. Balbir Bindra 2. Calum Morrison | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | 1. Non-Executive Director 2. Non-Executive Director | ||||
| b) | Initial notification/amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Craven House Capital PLC | ||||
| b) | LEI | 213800NY9RH8O1B72D27 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument | Ordinary Shares of $1.0 | ||||
| Identification code | GB00BD4FQ360 | |||||
| b) | Nature of the Transaction | Issue of ordinary shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume / price | Aggregate volume: 9,808 Aggregated price: $0 | ||||
| e) | Date of the transaction | 27 February 2020 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM | ||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.